Compare MI & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MI | VIVS |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | 9 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.9M |
| IPO Year | 2022 | N/A |
| Metric | MI | VIVS |
|---|---|---|
| Price | $10.23 | $1.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.4K | ★ 74.1K |
| Earning Date | 05-07-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.95 |
| 52 Week High | $19.84 | $5.30 |
| Indicator | MI | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 33.65 |
| Support Level | $3.51 | N/A |
| Resistance Level | $19.15 | $1.38 |
| Average True Range (ATR) | 1.17 | 0.08 |
| MACD | -0.94 | -0.00 |
| Stochastic Oscillator | 1.18 | 36.51 |
NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.